|
Orthologous residues
|
|
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'brain, hypothalamus', 293 (epithelial)
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
tunicamycin
|
|
|
|
decrease
|
|
|
leptin
|
tunicamycin
|
|
|
inhibit treatment-induced decrease
|
|
|
DTT
|
|
|
|
decrease
|
|
|
leptin
|
DTT
|
|
|
inhibit treatment-induced decrease
|
|
|
|
|
XBP1 (mouse)
|
|
no change compared to control
|
|
|
leptin
|
|
|
|
increase
|
|
|
tunicamycin
|
leptin
|
|
|
no effect upon treatment-induced increase
|
|
|
|
|
ATF6 (mouse)
|
|
no change compared to control
|
|
|
leptin
|
|
|
|
increase
|
|
|
tunicamycin
|
leptin
|
|
|
no effect upon treatment-induced increase
|
|
|
leptin
|
|
|
|
increase
|
wild-type (lean) mice
|
|
leptin
|
|
|
|
decrease
|
ob/ob (obese) mice
|
|
|
|
